Knockdown of Rhotekin 2 expression suppresses proliferation and invasion and induces apoptosis in hepatocellular carcinoma cells

Wei,Wei; Chen,Huabing; Liu,Sibin

doi:10.3892/mmr.2016.5113

Knockdown of Rhotekin 2 expression suppresses proliferation and invasion and induces apoptosis in hepatocellular carcinoma cells

Authors:
- Wei Wei
- Huabing Chen
- Sibin Liu
View Affiliations

Affiliations: Department of Radiology, Jingzhou Central Hospital, Jingzhou, Hubei 434020, P.R. China
Published online on: April 13, 2016 https://doi.org/10.3892/mmr.2016.5113
Pages: 4865-4871

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC), which is one of the most common types of cancer worldwide, has been ranked as the third leading cause of cancer‑associated mortality worldwide. Rhotekin 2 (RTKN2), a Rho‑guanosine triphosphatase (GTPase) effector, has been reported to be anti‑apoptotic. However, the molecular mechanism underlying the biological function of RTKN2 in HCC is poorly defined. The current study reported that RTKN2 was overexpressed in 83% of HCC specimens compared with adjacent noncancerous tissues (n=30). Depletion of RTKN2 in HCC cells, HepG2 and BEL‑7404 by RNA interference led to marked inhibition of cell proliferation and cell cycle progression. Notably, RTKN2 silencing significantly reduced the levels of cell cycle‑associated proteins, proliferating cell nuclear antigen and cyclin‑dependent kinase 1. Additionally, it was identified that downregulation of RTKN2 in HCC cells notably induced cell apoptosis, while significantly repressing cell invasion. These data suggest that RTKN2 may act as an oncogene and inhibition of RTKN2 may be part of a novel therapeutic strategy for targeted HCC therapy.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Bosch FX, Ribes J, Díaz M and Cléries R: Primary liver cancer: Worldwide incidence and trends. Gastroenterology. 127(5 Suppl 1): S5–S16. 2004. View Article : Google Scholar : PubMed/NCBI
3	Finn RS: Development of molecularly targeted therapies in hepatocellular carcinoma: Where do we go now? Clin Cancer Res. 16:390–397. 2010. View Article : Google Scholar : PubMed/NCBI
4	Collier FM, Gregorio-King CC, Gough TJ, Talbot CD, Walder K and Kirkland MA: Identification and characterization of a lymphocytic Rho-GTPase effector: Rhotekin-2. Biochem Biophys Res Commun. 324:1360–1369. 2004. View Article : Google Scholar : PubMed/NCBI
5	Reid T, Furuyashiki T, Ishizaki T, Watanabe G, Watanabe N, Fujisawa K, Morii N, Madaule P and Narumiya S: Rhotekin, a new putative target for Rho bearing homology to a serine/threonine kinase, PKN and rhophilin in the rho-binding domain. J Biol Chem. 271:13556–13560. 1996. View Article : Google Scholar : PubMed/NCBI
6	Karlsson R, Pedersen ED, Wang Z and Brakebusch C: Rho GTPase function in tumorigenesis. Biochim Biophys Acta. 1796:91–98. 2009.PubMed/NCBI
7	Liu CA, Wang MJ, Chi CW, Wu CW and Chen JY: Rho/Rhotekin-mediated NF-kappaB activation confers resistance to apoptosis. Oncogene. 23:8731–8742. 2004. View Article : Google Scholar : PubMed/NCBI
8	Liu CA, Wang MJ, Chi CW, Wu CW and Chen JY: Overexpression of rho effector rhotekin confers increased survival in gastric adenocarcinoma. J Biomed Sci. 11:661–670. 2004. View Article : Google Scholar : PubMed/NCBI
9	Collier FM, Baker AJ, Walder K, Stupka N, Martin SD and Kirkland MA: A Rho-GTPase effector, rhotekin-2 (RTKN2) is associated with BMP8b and IL-16 cytokine expression anti increased sensitivity to apoptosis in lymphocytes. Blood amer soc hematology 1900 M street. NW suite 200, Washington, DC 20036 USA: pp. 679A–680A. 2007
10	Collier FM, Loving A, Baker AJ, McLeod J, Walder K and Kirkland MA: RTKN2 induces NF-KappaB dependent resistance to intrinsic apoptosis in HEK cells and regulates BCL-2 genes in human CD4(+) lymphocytes. J Cell Death. 2:9–23. 2009.PubMed/NCBI
11	Li W, Wu YF, Xu RH, Lu H, Hu C and Qian H: miR-1246 releases RTKN2-dependent resistance to UVB-induced apoptosis in HaCaT cells. Mol Cell Biochem. 394:299–306. 2014. View Article : Google Scholar : PubMed/NCBI
12	Gregorio-King CC, Gough T, Van Der Meer GJ, Hosking JB, Waugh CM, McLeod JL, Collier FM and Kirkland MA: Mechanisms of resistance to the cytotoxic effects of oxysterols in human leukemic cells. J Steroid Biochem Mol Biol. 88:311–320. 2004. View Article : Google Scholar : PubMed/NCBI
13	Saha SK, Roy S and Khuda-Bukhsh AR: Ultra-highly diluted plant extracts of Hydrastis canadensis and Marsdenia condurango induce epigenetic modifications and alter gene expression profiles in HeLa cells in vitro. J Integr Med. 13:400–411. 2015. View Article : Google Scholar : PubMed/NCBI
14	Papavasiliou FN and Schatz DG: Cell-cycle-regulated DNA double-strand breaks in somatic hypermutation of immunoglobulin genes. Nature. 408:216–221. 2000. View Article : Google Scholar : PubMed/NCBI
15	Ye G, Qin Y, Lu X, Xu X, Xu S, Wu C, Wang X, Wang S and Pan D: The association of renin-angiotensin system genes with the progression of hepatocellular carcinoma. Biochem Biophys Res Commun. 459:18–23. 2015. View Article : Google Scholar : PubMed/NCBI
16	Kubben FJ, Peeters-Haesevoets A, Engels LG, Baeten CG, Schutte B, Arends JW, Stockbrügger RW and Blijham GH: Proliferating cell nuclear antigen (PCNA): A new marker to study human colonic cell proliferation. Gut. 35:530–535. 1994. View Article : Google Scholar : PubMed/NCBI
17	Ferrell JE Jr, Wu M, Gerhart JC and Martin GS: Cell cycle tyrosine phosphorylation of p34cdc2 and a microtubule-associated protein kinase homolog in Xenopus oocytes and eggs. Mol Cell Biol. 11:1965–1971. 1991. View Article : Google Scholar : PubMed/NCBI
18	Wong CC, Wong CM, Au SL and Ng IO: RhoGTPases and Rho-effectors in hepatocellular carcinoma metastasis: ROCK N'Rho move it. Liver Int. 30:642–656. 2010. View Article : Google Scholar : PubMed/NCBI
19	Grise F, Bidaud A and Moreau V: Rho GTPases in hepatocellular carcinoma. Biochim Biophys Acta. 1795:137–151. 2009.PubMed/NCBI
20	Leber MF and Efferth T: Molecular principles of cancer invasion and metastasis (review). Int J Oncol. 34:881–895. 2009.PubMed/NCBI